Pegaptanib Provides Benefit for Neovascular Age-Related Macular Degeneration
Massachusetts Eye and EarResults from two concurrent, prospective, double-blind, multi-center clinical trials show that pegaptanib (Macugen), an anti-vascular endothelial growth factor therapy, is an effective treatment for neovascular age-related macular degeneration (AMD).